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Minor ischemic strokes and transient ischemic attacks involve impaired perfusion 
to corresponding brain regions leading to neurological deficits that may or may not resolve 
after the event. Adults suffering one of these minor neurovascular events have high odds 
of a recurrent stroke within the first 90 days, mitigated but not prevented by standard 
treatment of clopidogrel and aspirin. Vitamin E alpha-tocopherols have been shown to 
reduce platelet aggregation, potentiate aspirin, and reduce ischemic damage. This study 
will assess the efficacy of vitamin E alpha-tocopherol, in addition to the standard treatment, 
on stroke recurrence in adults with a minor neurovascular event compared to the standard 
treatment alone. In this randomized, double-blinded, placebo-controlled trial, participants 
will receive the standard treatment of clopidogrel and aspirin with either vitamin E alpha-
tocopherol or placebo supplements. This study may help decrease the proportion of stroke 










Cerebrovascular accidents, or strokes, are a leading cause of disability in the United 
States with 800,000 people suffering from a new or recurrent stroke a year. Strokes may 
be due to ischemia, a subarachnoid hemorrhage, or an intracerebral hemorrhage with 87% 
of all strokes having an ischemic etiology.1 An ischemic stroke involves arterial occlusion 
or blockage resulting in reduced blood perfusion to corresponding brain regions leading to 
neurological deficits. Ischemic strokes are subcategorized into mild, moderate, and severe 
by the National Institute of Health Stroke Scale (NIHSS), a 42-scale scoring system that is 
utilized to quantify stroke severity in patients. A minor ischemic stroke is classified by a 
NIHSS score ≤ 3.2-4A transient ischemic attack (TIA) occurs when there is temporary 
occlusion of a blood vessel causing brief neurological symptoms that resolve within 24 
hours before an ischemic injury occurs. TIA’s precede approximately 15% of all 
cerebrovascular accidents and 33% of all ischemic strokes.5,6 The ABCD2 7-scale score 
predicts the stroke recurrence risk at 2-days, 7-days, and 90-days in patients who have a 
TIA. A patient who has a TIA that is at moderate to high-risk of a recurrent stroke is defined 
by an ABCD2 score ≥ 4. 7-9  
Unfortunately, both minor ischemic strokes and transient ischemic attacks place 
patients at a high-risk of a subsequent stroke with sources suggesting a recurrence risk 
ranging from 3-17% within the first 90 days of the primary neurovascular event.10-18 We 
propose a trial to reduce stroke recurrence in patients with a primary neurovascular event 
using vitamin E supplements. Currently, patients with a moderate to high-risk TIA or minor 
ischemic stroke with an identified thrombotic etiology are given antiplatelet therapy to 
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prevent a recurrent ischemic event. The regimen that is often prescribed is aspirin and 
clopidogrel (DAPT) but the regimen has its limitations.12,13  
The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) 
study was an international, multi-center study that determined that DAPT was associated 
with a significantly lower risk of stroke recurrence (hemorrhagic and ischemic) compared 
to aspirin alone (HR, 0.74; 95% CI, 0.58 to 0.94). Of note, there was a significant increase 
in the risk of major hemorrhage in the DAPT group compared to the aspirin alone group 
(0.9% vs 0.4%, HR, 2.32, 95% CI, 1.10 to 4.87).12 In a similar China based trial, 
clopidogrel and aspirin were administered for 21 days followed by clopidogrel for the 
remainder of 90 days had a significant decrease in recurrent strokes (hemorrhagic and 
ischemic) compared to aspirin alone (8.2% vs 11.7%; HR, 0.68; 95% CI, 0.57 to 0.81). 13 
DAPT has been shown to decrease stroke recurrence in TIA and minor ischemic stroke 
patients when used for less than a month. However, treatment surpasses 1 month, there is 
a significant increase in major bleeding events.19 This study aims to determine if there is a 
difference in the proportion of patients experiencing recurrent strokes (hemorrhagic or 
ischemic) in patients who receive vitamin E alpha-tocopherol supplements in addition to 
the standard treatment compared to patients who receive the standard treatment alone after 
the initial minor neurovascular event.  
There are several mechanisms that vitamin E alpha-tocopherol takes part in that 
support its use in this trial. Several studies suggest that alpha-tocopherol inhibits protein 
kinase C stimulation (PKC) leading to an increase in nitric oxide (NO) and decrease in free 
radicals.20-24 NO then activates cyclic guanosine monophosphate (cGMP) causing 
inhibition of platelet aggregation.25,26 In addition, alpha-tocopherol inhibits 
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cyclooxygenase (COX) and as a result, when combined with aspirin, antiplatelet effects 
are potentiated.22,27,28 If alpha-tocopherol reduces platelet aggregation then it may play a 
role in reducing the incidence of secondary ischemic events, including ischemic stroke, 
post-minor neurovascular event.  
Both animal studies and human studies support the aforementioned mechanism of 
vitamin E alpha-tocopherol. Animal studies have shown that both alpha-tocopherol alone 
and in combination with aspirin have led to less platelet aggregation and a longer time to 
thrombus formation compared to no alpha-tocopherol or aspirin alone, respectively.21,24,29 
The studies have also suggested that vitamin E alpha-tocopherol protected cortical neurons 
from damage under ischemic conditions.24,28  Human in-vitro studies have further validated 
vitamin E alpha-tocopherol’s mechanism through a reduction in platelet aggregation both 
alone and in combination with aspirin.22,24,25,30,31 A human in-vivo study showed a 
reduction in primary ischemic strokes when used as an oral supplement alone for 6 years 
in male smokes compared to male smokers with placebo supplements.32 However, only 
one in-vivo study has investigated vitamin E alpha-tocopherol’s effects on stroke 
recurrence. A study from 1995 found that 400IU vitamin E alpha-tocopherol plus 325mg 
of aspirin for 2 years in patients with a TIA or minor ischemic stroke had a 2% recurrence 
risk compared to 12.5% in patient’s taking 325mg aspirin alone (P<0.05). There was a 
5.7% recurrence risk of total stroke (hemorrhagic or ischemic) in the vitamin E plus aspirin 
group compared to 12.5% in the group that took aspirin alone (P<0.05). Unfortunately, the 
study has many limitations and the study has not been reproduced with the current DAPT.33  
Despite the preventative treatment for stroke recurrence, there remains to be a high 
incidence of disability among patients with a TIA or minor ischemic stroke. New treatment 
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regimens are needed to reduce the burden that this high-risk population faces. Although 
vitamin E alpha-tocopherol appears to have a promising mechanism, the literature is 
lacking studies that have investigated secondary prevention of stroke recurrence with short 
term use of alpha-tocopherol. Given the proposed mechanisms of alpha-tocopherol, this 
study aims to determine the association of 200IU vitamin E alpha-tocopherol oral 
supplements on stroke recurrence when given for 90 days in addition to the antiplatelet 
regimen in patients with a transient ischemic attack or minor ischemic stroke and compare 
it to patients taking clopidogrel and aspirin alone. By doing so, it may be possible to reduce 
the proportion of stroke recurrence (hemorrhagic or ischemic) in this high-risk population 
thus reducing mortality and morbidity. 
 
1.2 Statement of the Problem 
  
Strokes are a leading cause of morbidity and mortality in the United States population. 
Although great strides have been made in our understanding of strokes and their 
pathophysiologic consequences, they continue to be a daunting experience for physicians 
and patients alike. Specifically, there remains to be approximately an 8.2% stroke 
(ischemic and hemorrhagic) recurrence risk among patients with a primary transient 
ischemic attack or minor ischemic stroke that ultimately leads to disability, death hospital 
crowding, and high billing costs.13,34 Approximately one-half of patient’s that experience 
a recurrent stroke become disabled.34 By demonstrating the effectiveness of an alternative 
treatment regimen, this study may not only reduce the burden among healthcare providers 
and the healthcare system, but more importantly the quality of life of people who suffer 
from minor neurovascular events.  
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Literature suggests vitamin E alpha-tocopherols have antiplatelet, antioxidant, and 
aspirin potentiation properties. However, studies lack examining this mechanism with the 
current standard treatment in specifically this high-risk population. Therefore, we will 
perform a randomized, multi-center, placebo-controlled study to demonstrate the 
effectiveness of vitamin E alpha-tocopherol in the prevention of secondary ischemic 
strokes and compare it to the currently accepted standard of clopidogrel and aspirin. 
 
1.3 Goals and Objectives 
 
The randomized, multi-center, double-blinded, placebo-controlled trial aims to assess 
the efficacy of vitamin E alpha-tocopherol supplements, plus the standard treatment, in 
reducing the proportion of stroke recurrence in patients with a primary transient ischemic 




Patients with a transient ischemic attack (ABCD2 ≥ 4) or minor ischemic stroke (NIHSS 
≤ 3) over the age of 18 years who are treated with 200IU vitamin E alpha-tocopherol in 
addition to the standard treatment of aspirin and clopidogrel will have a statistically 
significant difference in the proportion of stroke recurrence (hemorrhagic or ischemic) 









ABCD2 Score: A 7-scale score that predicts the risk of stroke recurrence of a person with 
a transient ischemic attack. Scoring considers age, blood pressure, clinical features, 
duration of symptoms, and diabetes.9 Scoring can be found in Appendix C. 
Alpha-Tocopherol: Alpha-tocopherol is one of the eight components of the antioxidant, 
vitamin E, and the most predominant form with the chemical formula of C29H50O2.
35 
Aspirin (Acetylsalicylic Acid/ASA): A synthetic, anti-inflammatory and antiplatelet 
agent that non-selectively and irreversibly inhibits COX-1and COX-2 enzymes. 
Clopidogrel (Plavix): A synthetic, pharmaceutical, antiplatelet agent that irreversibly 
inhibits adenosine phosphate-induced platelet aggregation. 
Minor Ischemic Stroke: A minor ischemic stroke is involving occlusion of the brain 
vessels resulting in a decrease in blood flow to the corresponding brain structures resulting 
in focal deficits. Specifically, a minor ischemic stroke is defined by a NIHSS score ≤ 3.  
NIH Stroke Scale (NIHSS): A 42-scale scoring system that is utilized to quantify stroke 
severity in patients, taking into consideration the patient’s level of consciousness, gaze 
ability, visual ability, facial paralysis, extremity motor drift, lower limb ataxia, sensation, 
aphasia, dysarthria, and extinction.4 Full scoring can be found in Appendix E. 
Transient Ischemic Attack (TIA): A brief, non-ischemic arterial occlusion in the brain 
that causes focal neurological deficits, lasting no longer than 24 hours. A patient with a 
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CHAPTER 2: REVIEW OF THE LITERATURE  
 
2.1 Literature Search Strategy 
 
A literature review was conducted between July 2020 and March 2021 using Ovid 
(Medline), Scopus, The Cochrane Library, and PubMed with the help of the Yale School 
of Medicine librarians. Studies were initially selected based on the title and abstract that 
were relevant to our proposed trial. International trials were included into the review based 
on the relevance of the study and its contribution to the progression of the literature. 
Initially, our research was confined to 2010 but was then extended to 1980 and beyond to 
include significant, pertinent trials that contributed to the development of this proposed 
trial. 
 Search strategy utilized the following MeSH headings and terms: TIA, transient 
ischemic attack, minor ischemic stroke, ischemic stroke, strokes, vitamin E, vitamin E 
alpha-tocopherol, alpha-tocopherol, tocopherols, recurrence, stroke recurrence, 
prevention, secondary prevention, treatment, therapy, clopidogrel, aspirin, DAPT, dual 
antiplatelet therapy, dual antiplatelet treatment, antiplatelet, platelet aggregation, 
thrombosis, antithrombosis, anticoagulation, nitric oxide, NO, vascular, neurovascular, 
antioxidant, oxidant, mechanism, mechanism of action and adults. 
 
2.2 Review of Empirical Studies  
  
2.2.1 Minor Neurovascular Events 
 
We will define minor neurovascular events as a moderate to high-risk transient 
ischemic attack (TIA) and minor ischemic stroke. Specifically, a moderate to high-risk TIA 
will be classified as an ABCD2 score of equal to or greater than 4. The ABCD2 7-scale 
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system determines a patient’s risk of recurrent stroke (Appendix C). In one study, patients 
with a high-risk TIA (ABCD2 ≥ 6) had an 8.1% 2-day risk and a 36-43% 90-day risk of a 
recurrent stroke. Patients with a moderate risk TIA (ABCD2 = 4 or 5) had a 4.1% 2-day 
risk and 19-24% 90-day recurrence risk. Patients with a low-risk TIA (ABCD2 = 0 to 3) 
had a 1.0% risk and 0-7% 90-day recurrence risk.1,2 A study validated the scoring system 
by using it across different independent groups of patients.1 Given the validity of the 
scoring in the ability to predict increased risk of secondary stroke in patients with a 
moderate to high-risk TIA and evidence suggesting that a higher ABCD2 score has a greater 
likelihood of being a true TIA (not a misdiagnosis), we will include patients with a 
moderate to high-risk TIA (ABCD2 ≥ 4).  
 A minor ischemic stroke will be defined as a National Institute of Health Stroke 
Scale (NIHSS) score as less than or equal to 3. The NIHSS scoring is a 42-point scale 
accounts for the level of consciousness, gaze ability, visual ability, facial paralysis, 
extremity motor drift, lower limb ataxia, sensation, aphasia, dysarthria, and extinction 
(Appendix E).3 However, there is controversy on whether a NIHSS score of 4 or 5 should 
be classified as a minor stroke as well. The literature that has specifically looked at 
clopidogrel and aspirin included patients with a minor ischemic stroke with a NIHSS of 
less than or equal to 3 so we will use the same scoring to define our minor ischemic stroke 
population.4,5   
Patients with a minor neurovascular event are at high risk of a subsequent stroke 
with sources demonstrating a recurrence risk ranging from 3-17% within the first 90 days 
of the index event.4-10 It is estimated that 50% of those who have a recurrent stroke will 
experience the event within weeks of the ischemic stroke with the risk decreasing and 
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remaining steady by 6 to 12 months after the primary event.5 The recurrent event often 
leads to disability and can lead to death. Recurrent stroke events may occur with worsening 
of the primary stroke through plaque formation and/or vasoconstriction causing ischemia 
or a new atheroembolic, cardioembolic, or hemorrhagic stroke after resolution of the 
primary stroke.11,12 Patients with a TIA or minor ischemic stroke with an identified 
thrombotic etiology are given antiplatelet therapy to prevent a recurrent ischemic event. 
This section will discuss the different regimens for preventing a secondary ischemic stroke.  
 
2.2.2 Current Treatment of Minor Neurovascular Events 
 
2.2.2.1 Aspirin + Clopidogrel  
 
Figure 1: Proposed Alpha-Tocopherol Mechanism Adapted from Gkaliagkousi et al.13-20  
AA: arachidonic acid; AC: adenylyl cyclase; ATP: adenosine triphosphate; Ca2+: Calcium; cAMP: cyclic 
adenosine monophosphate; cGMP: cyclic guanosine monophosphate; COX-1: cyclooxygenase-1; DAG: 1,2-
diacylglycerol; eNOS: endothelial nitric oxide synthase; IP3: inositol 1,4,5-trisphosphate; NO: nitric oxide; 
O2-: superoxide; ONOO-: peroxynitrite; P2Y12: adenosine diphosphate receptor; PKC: protein kinase c; 
PLA2: phospholipase a2; PLCβ: phospholipase cβ; ROS: reactive oxygen species; TXA2: thromboxane 2. 
Solid arrows indicate activation, dashes indicate inhibition.  
 
 This section will review the accepted dual-antiplatelet therapy (DAPT) of 
clopidogrel and aspirin that is used to prevent recurrent strokes in patients with a moderate 
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to high-risk transient ischemic attack (TIA) or minor ischemic stroke. A multitude of 
randomized controlled trials have assessed the efficacy of DAPT versus antiplatelet 
monotherapy. DAPT has since become a widely accepted and recommended regimen to 
prevent stroke recurrence for this patient population.21 The two pharmaceutical drugs are 
thought to work synergistically to reduce platelet aggregation causing a reduction in stroke 
recurrence risk compared to antiplatelet monotherapy.22,23 
 However, there is debate in the literature over the efficacy of DAPT compared to 
antiplatelet monotherapy. The MATCH trial was a double-blinded, multi-center, placebo-
controlled study that randomized patients over 40 years old with a recent ischemic stroke 
or TIA and an additional vascular risk factor to receive an 18-month course of DAPT or 
clopidogrel alone. There was no significant difference between DAPT and clopidogrel 
alone (15.7% vs 16.7%, RR reduction 6.4%; 95% CI, -4.6 to 16.3). Notably, participants 
in the DAPT group had significantly more life-threatening bleeds than participants who 
received only clopidogrel (2.6% vs 1.3%; absolute risk increase 1.3%, 95% CI, 0.6 to 
1.9).24 It is important to note that the antiplatelet therapy was given for a course of 18 
months but time to event analysis was not performed to determine if the increased risk of 
bleeding could be due to prolonged antiplatelet use. The trial also had a broad inclusion 
criterion that allowed participants to join if they had an ischemic stroke or TIA in the past 
3 months. While broad inclusion criteria tend to increase external validity and 
generalizability, studies have shown that the risk of recurrent stroke is highest within 90 
days of the index event.25 Additionally, trials have shown that DAPT should be given 
within 12 to 24 hours of the event to have maximum benefit.4,5 Studies have also shown a 
benefit of DAPT in patients with a TIA with an ABCD2 score of greater than or equal to 4 
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or a minor ischemic stroke with a NIHSS score of less than or equal to 3.4,5,9 DAPT is not 
the recommended treatment for cardioembolic strokes, minor TIA’s, moderate and severe 
minor ischemic strokes.21  
 The CHARISMA trial, a multi-center, double-blinded, placebo-controlled study, 
randomized 15,603 participants, over the age of 45 years with risk factors for 
atherothrombotic events, such as diabetes, smoking, coronary disease, and cerebrovascular 
disease, to receive DAPT of clopidogrel and aspirin or aspirin alone for a median of 28 
months. There was no significant difference in severe bleeding (RR, 1.25; 95% CI, 0.97 to 
1.61; P=0.09) or in intracranial hemorrhage (RR, 0.96; 95% CI, 0.56 to 1.65; P=0.89), or 
in the composite of myocardial infarctions, strokes, or mortality from cardiovascular causes 
(RR, 0.93; 95% CI, 0.83 to 1.05; P= 0.22) between the two groups. Notably, participants 
in the DAPT group had a significantly greater risk of developing moderate bleeding (RR, 
1.62; 95% CI, 1.27 to 2.08; P<0.001) but a lower risk of having a non-fatal stroke (RR, 
0.03; 95% CI, 0.64 to 0.98; P=0.03) or hospitalization from unstable angina, TIA, or 
revascularization (RR, 0.90; 95% CI, 0.82 to 0.98; P=0.02) compared to participants taking 
aspirin alone. Only 37% of participants in each group had a history of a stroke or TIA. No 
subgroup analysis was performed for these participants.26 Neither the MATCH nor the 
CHARISMA trial fully captured our target population. For the purpose of this study, we 
will focus specifically on the literature that investigated DAPT in patients with minor 
ischemic strokes and TIA’s as it has shown to be more efficacious in reducing stroke 
recurrence compared to antiplatelet monotherapy. 
The POINT study was a multi-center, randomized, double-blinded, placebo-
controlled international trial that randomized 4,881 patients over 18 years old with a minor 
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ischemic stroke (NIHSS  3) or moderate to high-risk TIA (ABCD2  4) within 12 hours 
of symptom onset to receive either a 90-day course of DAPT of clopidogrel and aspirin or 
aspirin alone with placebo tablets. The study found that patients who received DAPT had 
a significantly lower risk of having major ischemic events (ischemic stroke, myocardial 
infarction, or death from an ischemic vascular event) at 90 days compared to patients taking 
aspirin alone (5% vs 6.5%; HR, 0.75; 95% CI, 0.59 to 0.95; P=0.02). Most ischemic events 
occurred during the first week after the index event. Patients in the DAPT group had a 
significantly greater risk of developing a major hemorrhage compared to patients who 
received aspirin alone (0.9% vs 0.4%; HR, 2.32; 95% CI, 1.10 to 4.87; P=0.02). However, 
there was no significant difference in death from hemorrhagic etiology in either group 
(0.1% vs 0.1%). The study had a large sample size, randomized the participants, and 
blinded both participants and researchers. This increases the internal validity and thus 
strengthens the findings between DAPT and aspirin alone. The trial also increased the 
external validity of the trial by including multiple international centers, thus enhancing the 
generalizability of the trial.  
The CHANCE trial, similarly, sought to determine the efficacy of short-term DAPT 
of clopidogrel and aspirin followed by clopidogrel alone to prevent secondary ischemic 
strokes in patients in China with a moderate to high-risk TIA or minor ischemic stroke. 
Participants that met the eligibility criteria within 24 hours of their index event were 
randomized to either receive a 21-day course of DAPT followed by clopidogrel alone from 
day 22 to day 90 or aspirin plus placebo tablets for the full 90 days. 8.2% of participants 
that received DAPT had a stroke (ischemic or hemorrhagic) by day 90 while 11.7% of 
participants in the aspirin alone group had a stroke (ischemic or hemorrhagic) by day 90 
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(HR, 0.68; 95% CI, 0.57 to 0.81; p < 0.001). More specifically, ischemic stroke occurred 
in 7.9% in the DAPT group vs 11.4% in the aspirin alone group (HR, 0.67; 95% CI, 0.56 
to 0.81; p < 0.001). In addition, hemorrhagic stroke occurred in 0.3% of participants in 
each group (P=0.93) and moderate or severe hemorrhaging, as defined by the GUSTO 
criteria (Table 4) occurred in 0.3% of participants in each group P = 0.73). There was a 
trend in overall bleeding in the DAPT group, however this was not significant when 
compared to the aspirin alone group, unlike the finding in the POINT trial.4,5 It is important 
to note that although this trial was large, involving 5,170 patients from 114 centers, it was 
specific towards patients in China, decreasing external validity.5 However, similar trials 
investigating DAPT, including the POINT trial included the US, the CARESS trial done in 
Europe, and the CLAIR trial done in Asia, all support the regimen’s greater efficacy in 
reducing stroke recurrence, ischemic in particular, compared to aspirin alone.4,27,28 Given 
the large sample size in the CHANCE trial and equal risk of developing moderate to severe 
hemorrhage and hemorrhagic stroke between groups (0.3% vs 0.3%, p=0.73), it was 
accepted into the guidelines for high-risk TIA/minor ischemic stroke treatment guidelines 
by the American Heart Association.5,21   
 A meta-analysis that included five randomized controlled trials, including the 
POINT, CHANCE, and CARESS trial recently described, found that short term DAPT of 
aspirin and clopidogrel for 1 month or less significantly reduced the risk of recurrent 
ischemic stroke (RR, 0.53; 95% CI, 0.27-0.78) and major cardiovascular events (RR, 0.72; 
05%CI, 0.58-0.90) and did not increase the risk of major bleeding (RR, 1.82; 95% CI, 1.36-
2.56) compared to aspirin alone. Similarly, DAPT given for 1 to 3 months (intermediate 
term) significantly reduced the risk of recurrent ischemic stroke (RR, 0.72; 95% CI, 0.58-
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0.90) and cardiovascular events (RR, 0.76; 95% CI, 0.61-0.94).  However, participants 
given DAPT for the intermediate term had an increased risk of major bleeding events 
compared to participants who received DAPT for the short term (RR, 2.58; 95% CI, 1.19-
5.60). Participants who took DAPT for the long-term (over 3 months) had no significant 
reduction in the risk of recurrent ischemic stroke (RR, 0.81; 95% CI, 0.63-1.04) or in 
adverse cardiovascular events (RR, 0.87; 95% CI, 0.71-1.07) and showed a significantly 
increased risk of major bleeding compared to participants who received DAPT for the short 
term (RR, 1.82; 95% CI, 0.91-3.62).29 The majority of the participants that were included 
in this study had a minor ischemic stroke and TIA patients. A couple of studies included 
ischemic stroke patients were specific to lacunar strokes.30,31 The studies also varied on the 
dosing of both clopidogrel and aspirin, which could have altered the meta-analysis results.  
When looking specifically at moderate to high-risk TIA and minor ischemic stroke 
patients, however, a multitude of studies have found a benefit to using DAPT, specifically 
clopidogrel and aspirin, to reduce the risk of developing a recurrent ischemic 
stroke.4,5,27,29,31 However, studies have varied in their length of onset to treatment, duration 
of the DAPT and dosing. This variability could explain the argument regarding dual 
antiplatelet therapy versus antiplatelet monotherapy when balancing ischemic stroke 
recurrence and hemorrhaging. 
 
2.2.2.2 Other Treatments 
 
Aspirin + Ticagrelor 
 Trials have been exploring new secondary prevention strategies to reduce stroke 
recurrence in patients with a moderate to high-risk transient ischemic attack (TIA) or minor 
ischemic stroke compared to other treatments. In an international double-blinded 
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controlled trial, patients with a moderate to high-risk TIA (ABCD2  4) or mild to moderate 
ischemic stroke (NIHSS  5) were randomized within 24 hours of the index event to receive 
a 90-day course of either ticagrelor, an antiplatelet agent, or aspirin. There was no 
significant difference in stroke occurrence, myocardial infarction, or death within 90 days 
in patients who took ticagrelor plus aspirin versus aspirin alone (6.7% vs 7.5%, HR, 0.89, 
95% CI, 0.78 to 1.01, P = 0.07). Secondary analysis found no significant difference in 
ischemic stroke between the two groups (5.8% vs 6.7%, HR, 0.87, 95% CI, 0.76 to 1.00).32 
A similar international trial, double-blinded trial, patients with a high-risk TIA (ABCD2  
6) or minor to moderate ischemic stroke (NIHSS  5) were randomized within 24 hours of 
the index event to receive a 30-day regimen of either ticagrelor plus aspirin or aspirin plus 
placebo. There was a 5.5% chance of stroke or death within 30 days and 6.6% chance in 
the aspirin alone group (HR, 0.83; 95% CI, 0.71 to 0.96; P = 0.02). Specifically, ischemic 
stroke occurred in 5.0% in the ticagrelor-aspirin group and 6.3% in the aspirin group (HR, 
0.79; 95% CI, 0.68 to 0.93; P = 0.004). Significantly more participants experienced severe 
bleeding in the ticagrelor plus aspirin group than the participants in the aspirin alone group 
(0.5% vs 0.1%, P=0.001).9 Although, there may be a decrease in stroke recurrence in the 
ticagrelor-aspirin group within 30 days of the primary event, the trial did not fully capture 
the high risk of recurrent strokes that exist within the full 90 days. Further investigation is 
needed in the efficacy of ticagrelor and its potential role in dual antiplatelet therapy for the 
full 90 days and should be compared to the current standard of clopidogrel and aspirin. 
 
Aspirin + Dipyridamole  
Another potential regimen to prevent stroke recurrence is aspirin plus 
dipyridamole, an antiplatelet agent. In one study, participants with an ischemic stroke were 
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randomized to receive either aspirin plus dipyridamole or clopidogrel alone. There was a 
lower risk of mortality and subsequent stroke or myocardial infarction events within 90 
days in the aspirin plus dipyridamole group (HR, 0.62, 0.43 to 0.91; HR, 0.70, 0.52 to 
0.94).33 However, a different study found that patients taking aspirin plus dipyridamole had 
similar rates of recurrent strokes, compared to patients taking clopidogrel alone (9.0% vs 
8.8%, respectively, HR, 1.01, 95% CI, 0.92 to 1.11). The international, double-blinded, 
randomized trial involved 20,333 participants who had an ischemic stroke, defined by focal 
neurological symptoms lasting over 24 hours or evidence of an infarction on imaging, that 
were prescribed either 25mg aspirin plus 200mg extended-release dipyridamole twice daily 
or 75mg clopidogrel daily for 2.5 years.  Neither study mentioned represented patients with 
a transient ischemic attack and did not specify the severity of the ischemic stroke patients, 
decreasing the external validity of the trial.33,34 Despite the regimen’s possible role in stroke 
recurrence, multiple studies have shown that almost half of patients on dipyridamole had a 
headache that resulted in a significant number of patients to discontinue the drug.34-36   
 
2.2.3 Vitamin E Alpha-Tocopherol as a Potential Treatment 
 Vitamin E is a collection of fat-soluble molecules known as tocopherols and 
tocotrienols. Alpha-tocopherol, in particular, is the most widely available and studied 
component of vitamin E.37,38 This section will discuss the different proposed mechanisms 
of vitamin E alpha-tocopherol including inhibition of platelet aggregation, potentiation of 
aspirin, and reduction in oxidative stress. The mechanisms suggest a possible role in 
reducing the incidence of stroke recurrence in patients with a high-risk transient ischemic 
attack (TIA) or minor ischemic stroke. 
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2.2.3.1 Antiplatelet Properties 
 Vitamin E alpha-tocopherol (AT) has been shown to inhibit protein kinase C 
(PKC), a platelet aggregate regulator, leading to an increase in nitric oxide (NO), decrease 
in superoxide, and decrease in lipid peroxidation.18,39-43 An increase in platelet NO leads to 
an increase in cyclic guanosine monophosphate (cGMP). cGMP activates cGMP-
dependent protein kinase (PKG) ultimately leading to inhibition of platelet aggregation.44,45 
The decrease in superoxide and lipid peroxidation contribute to AT’s antioxidant properties 
discussed later in this section. 
 Mice fed a high vitamin E diet for a mean of 15 days had significantly less platelet 
aggregation and a longer time to thrombus formation compared to mice fed a regular diet 
(P<0.05).46 Similarly, Li et al. found a significantly lower platelet count in mice that 
received 8-weeks of either low dose vitamin E supplements (P<0.01) or high dose vitamin 
E supplements (P<0.01) compared to mice who received placebo. There was a positive 
dose effect relationship in the vitamin E alpha-tocopherol dose and platelet count.47   
 In a study, human platelets were incubated with different alpha-tocopherol and 
found a significant decrease in adenosine diphosphate (ADP)-induced platelet aggregation 
compared to the control (P<0.05). In addition, there was a significant decrease in lipid 
peroxidation products an increase in NO compared to the control.47 ADP is a platelet 
aggregation activator that is also inhibited by clopidogrel as seen in Figure 1.48 In another 
study, it was found that peripheral blood from healthy volunteers incubated with vitamin 
E had significantly less platelet aggregation when induced with Phorbol 12-myristate 13-
acetate (PMA), a PKC activator, compared to control peripheral blood that was induced 
with PMA (P<0.05).49 Another study isolated platelet’s from human’s plasma and 
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significant reduction in platelet aggregation when infused with alpha-tocopherol compared 
to the vehicle of 5% ethanol (r = -0.78; P < 0.02). To determine the mechanism of the 
alpha-tocopherol, the study utilized PKC-dependent and independent platelet agonists. 
Alpha-tocopherol treated platelets inhibited PMA-induced phosphorylation of 47-kD 
proteins, substrates of the PKC. In the same study, patients were randomized to alpha-
tocopherol supplements of a dose ranging from 400, 800, or 1200IU/d for 14 days. Blood 
samples were then obtained by the participants. PKC-dependent agonist phorbol 12-
myristate 13-acetate (PMA) and alpha-tocopherol supplementation at all doses 
significantly has less platelet aggregation compared to pre-supplementation baseline (r 
=.67; P<0.01). While the findings are significant, it is notable that the study only included 
15 participants, decreasing the internal validity of the trial.40 
Similar findings have been seen in other trials. Participants who were supplemented 
with 400IU alpha-tocopherol daily for 14 days had a significant increase in NO production 
(P<0.05) and less ROS (P<0.05) compared to the control. The study also found that through 
immunoprecipitation, platelets incubated with alpha-tocopherol did not have PKC-
dependent eNOS phosphorylation, suggesting that alpha-tocopherol increases NO release 
through a PKC dependent mechanism.18 This trial also had a very small sample size of 5 
participants, decreasing the internal validity of the results. However, given the results of 
the aforementioned studies, it may be proposed that alpha-tocopherol inhibits platelet 
aggregation through the PKC pathway, as demonstrated in Figure 1. 
The antiplatelet mechanism of alpha-tocopherol has been supported clinically as well. 
Notably in the ATBC study, healthy men who were given 50mg (approximately 75IU) of 
alpha-tocopherol had a significantly lower risk of cerebral infarctions and no increased risk 
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of subarachnoid hemorrhages compared to those taking placebo (P=0.035; P=0.07).50 
Glynn et al. randomized participants over the age of 45 years old to receive 600IU of 
vitamin E or placebo for a median of 10.2 years. People in the vitamin E group had a 
significantly lower risk of developing a venous thromboembolism (VTE) (relative hazard, 
0.73; 95% CI, 0.66 to 0.94; P=0.010). The risk is lowered in those who had a history of a 
VTE (relative hazard, 0.56; 95% CI, 0.31 to 1.00; P=0.048), no history of a VTE (relative 
hazard, 0.82; 95% CI, 0.68 to 0.99; P=0.048), and a history of a factor V Leiden or 
prothrombin mutation (relative hazard, 0.51; 95% CI, 0.30 to 0.87; P=0.014).51 These 
results further support the antiplatelet properties of vitamin E.  
 
2.2.3.2 Aspirin Potentiation 
 In addition to the nitric oxide (NO) increase, research also suggests that alpha-
tocopherol increases prostacyclin synthesis through inhibition of phospholipase A2 and 
cyclooxygenase (COX) by a similar mechanism as aspirin as seen in Figure 1. As a result, 
when vitamin E alpha-tocopherol is used in combination with aspirin, the antiplatelet 
effects are potentiated resulting in a significant decrease in platelet aggregation.13,14,17,52  
Gonzalez-Correa et al. found that rats treated with vitamin E alone had significantly 
less platelet aggregation than saline treated rats (P<0.001). There was significantly less 
platelet aggregation in the rats treated with aspirin and alpha-tocopherol compared to the 
control/nondiabetic rats, the saline treated diabetic rats, the aspirin treated diabetic rats, and 
the alpha-tocopherol treated diabetic rats (P<0.05; P<0.0001; P=0.015; P=0.002, 
respectively). The combination of aspirin and alpha-tocopherol had greater inhibition of 
thromboxane production compared to alpha-tocopherol alone (P=0.038). The combination 
 23 
also potentiated prostacyclin production compared to alpha-tocopherol alone (P<0.0001) 
and aspirin alone (P<0.0001). Aspirin plus alpha-tocopherol also potentiated NO compared 
to alpha-tocopherol alone and aspirin alone (P=0.020, P=0.011, respectively). The study 
has limited external validity given a population of strictly type 1 diabetic rats. Of note, 
saline treated diabetic rats had significantly more platelet aggregation than the control 
nondiabetic rats (P<0.05). However, the aspirin and vitamin E alpha-tocopherol group did 
show significantly less platelet aggregation than the control non-diabetic rats (P<0.05). The 
study also supports the mechanism of alpha-tocopherol’s inhibition of thromboxane, 
increase in prostacyclin, increase in NO, and overall inhibition of platelet aggregation. 
These findings suggest vitamin E antiplatelet properties that synergistically work with 
aspirin and potentiate platelet aggregation inhibition.17 
Whole blood from healthy men was mixed with either aspirin alone or aspirin and 
alpha-tocopherol. NO was significantly higher in whole blood treated with both aspirin and 
alpha-tocopherol compared to aspirin alone resulting in less platelet aggregation (P<0.05). 
Vitamin E spared (at low doses) and significantly increased prostacyclin levels (at high 
doses) while aspirin significantly decreased prostacyclin synthesis (P<0.05) compared to 
the control. When alpha-tocopherol and aspirin were used together, there was significantly 
less prostacyclin inhibition compared to aspirin alone (IC50 12.92 ± 1.10uM vs IC50 1.81 ± 
0.15uM; P<0.05).14 In another study, human platelets were incubated with vitamin E and 
both the low dose, 50uM, (P<0.001) and high dose, 100uM, (P<0.001) inhibited platelet 
adhesion compared to platelets treated with aspirin alone. Because platelet activation was 
inhibited using collagen, the component that is exposed during endothelial damage thus 
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leading to recruitment of platelets, vitamin E has again shown to potentiate aspirin’s 
inhibition of platelet aggregation.52  
In one double-blinded, placebo-controlled trial 100 patients, over 18 years old, with 
a minor stroke, reversible ischemic neurologic deficit, retinal ischemic event, or TIA within 
8 weeks from enrollment were randomized to a 2-year course of either aspirin plus alpha-
tocopherol or aspirin alone. Patients who received aspirin plus alpha-tocopherol had a 
significantly lower risk of recurrent stroke (hemorrhagic or ischemic) compared to patient’s 
who took aspirin alone (5.7% vs 12.5%, P<0.05). There was no significant difference in 
hemorrhagic strokes between the two groups. Unfortunately, the trial has many issues. 
First, the study was not completed at the time of publication. At the time only 33 patients 
had reached a termination point and 16 patients had completed the 2-year study. Therefore, 
the analysis on recurrent stroke was only performed on about half of the total sample size 
of 100 patients. No follow-up study has been found for the complete study. So, while the 
preliminary results suggest a significant difference in stroke recurrence and platelet 
adhesion, the trial’s limitations must be considered.53 Notably, studies have not 
investigated short-term administration of vitamin E alpha-tocopherol nor in combination 
with antiplatelet drugs. Given the gap in the literature, this study will investigate further on 
the efficacy of alpha-tocopherol plus antiplatelet drugs on stroke recurrence in patients with 
high-risk TIA or minor ischemic stroke. This gap and study’s limitations further emphasize 





2.2.3.3 Antioxidant Properties 
Reactive oxygen species (ROS) are free radicals that damage cell membranes through 
lipid peroxidation. Lipid peroxidation is the process in which free radicals remove electrons 
from lipids that construct cell membranes. Removal of electrons cause disrupted, unstable 
cellular membranes that lead to cell death.54 Under standard conditions, ROS is produced 
through aerobic metabolism but is scavenged by endogenous antioxidants such as 
glutathione peroxidase and vitamin E thus preventing cell damage. Specifically, alpha-
tocopherol is a fat-soluble antioxidant that donates a hydrogen to inactivate free radicals, 
reducing lipid peroxidation and thus maintaining cellular membrane integrity.15,20 During 
an ischemic stroke, there is excessive metabolic production of ROS that are not scavenged 
causing neuronal cell death and possibly disability.55 Given alpha-tocopherol’s ability to 
bind to free radicals, supplements may have a potential role in reducing cell death and 
ultimately, reducing function deficit post-infarction.17,56   
In an animal trial, transient focal cerebral ischemia for 90 minutes was induced in 
rats. Rats who were pre-treated with alpha-tocopherol had significantly less brain edema 
(P < 0.001, 80.1 ± 0.32% vs 83.8 ± 0.11) and less disruption of the blood brain barrier (as 
seen by less Evans Blue leakage) (P < 0.001, 6.66 ± 0.87 µg/g vs 14.58 ± 1.29) compared 
to the control group. In addition, the alpha-tocopherol group had a significantly reduced 
concentration of malondialdehyde, an oxidative stress marker and marker of lipid 
peroxidation, (P < 0.001, 26.84 ± 4.79 nmol/mg vs 63.57 ± 5.42 nmol/mg) and elevated 
concentration of glutathione, an endogenous antioxidant, (P < 0.01, 10.17 ± 0.83 mmol/mg 
vs 5.86 ± 0.31 mmol/mg) compared to the control group post-ischemia. The alpha-
tocopherol group also had significantly diminished cerebral lesion volumes (P <0.01, 241 
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± 29 mm3 vs 422 ± 41mm3) and less severe motor disabilities (as measured by the 
neurological deficit score) (P <0.05, 1.75 ± 0.25 vs 4 ± 0.5) compared to the control group. 
These findings imply that pre-treatment with alpha-tocopherol may protect the brain from 
edema and disruption of the blood brain barrier through an antioxidant mechanism by 
reducing oxidative stress and increasing endogenous antioxidants leading to less cerebral 
death resulting in reduced disability severity compared to no pre-treatment.57  
Numakawa et al. found that 24 hour pretreated cultured cortical neurons from rats 
either alpha-tocopherol (P<0.001), alpha-tocotrienol (P<0.001), gamma-tocopherol 
(P<0.01), and gamma-tocotrienol (P<0.001) had significantly less neuronal death than the 
vehicle-treated neurons after H2O2 administration.55 Notably, both animal studies 
mentioned have limited external validity as they are specific to rats. However, the study 
may improve our understanding of mechanism of vitamin E and its potential role in 
reducing oxidative damage from ischemic stress. Research has shown that pre-treatment 
with vitamin E may be protective against cell damage and death if the animal undergoes 
an ischemic event.55,57 Therefore, vitamin E may not only help reduce the incidence of 
stroke but if a stroke occurs, it may reduce ischemic damage thus reducing the degree of 
disability if a recurrent ischemic stroke were to occur. 
Unfortunately, human trials investigating alpha-tocopherol’s antioxidant 
mechanism post-cerebral ischemia is limited. In one trial patients with an acute ischemic 
stroke were randomized to receive either 727 mg (800IU) alpha-tocopherol and 500mg of 
vitamin C or no treatment for 14 days. The study reproduced similar findings to the 
aforementioned animal studies, showing a reduction in the change in malondialdehyde 
concentration from day 0 to day 7 in patients who received vitamin E and C compared to 
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the control group (P<0.01, median -0.13umol/l vs 0.03, respectively). Patients treated with 
vitamin E and C also had a significantly greater median change from day 0 to day 7 of total 
antioxidant capacity compared to the control group (P<0.05, median 0.09mmol/l vs 0.01, 
respectively). The study had a small sample size of 48 participants and was performed at a 
single hospital in England thus limiting the external validity of the trial’s findings. The trial 
also combined vitamin E and C supplements and did not compare the effects of the drugs 
separately reducing the internal validity.58 Despite the study design of the aforementioned 
study, other human trials investigating other disorders have demonstrated that vitamin E 
alpha-tocopherol supplements at doses as low as 100IU is associated with a significantly 
lower malondialdehyde concentration and increased glutathione concentration, further 
supporting the vitamin E alpha-tocopherol antioxidant mechanism in humans.59-61  
The literature discussed has shown that alpha-tocopherol scavenges free radicals, 
increases endogenous antioxidants, reduces brain edema, protects the blood brain barrier, 
and ultimately, reduces disability severity. To further investigate vitamin E alpha-
tocopherols potential antioxidant effects, we will measure degree of disability using the 
modified Rankin Scale (mRS) at baseline and at day 90 and compare the mean change in 
mRS between groups. We will also compare mean mRS scores between groups in patients 
who had a recurrent stroke (ischemic or hemorrhagic) to investigate the relationship 
between disability in those were pre-treated with and without alpha-tocopherol. 
 
2.3 Identifying Potential Confounding Variables 
 There are several potential confounding variables that may influence stroke 
recurrence that need to be accounted for in this trial. Previous randomized controlled trials 
have investigated potential confounding variables and their potential effect on stroke 
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recurrence. A 2017 study performed a subgroup analysis of the CHANCE trial to determine 
potential risk factors associated with recurrent stroke in patients with dual antiplatelet 
therapy (DAPT). The study found that patients with a history of hypertension (P<0.009), 
history of smoking (P<0.02), higher body mass index (P<0.02), less likely to have a lipid 
lowering agent (P<0.01), and a baseline NIHSS score of 2 (HR 2.12; 95% CI, 1.07 to 4.21) 
or 3 (HR 4.11; 2.05 to 8.22) compared to those who did not have a stroke of DAPT.62 We 
will also control for diabetes mellitus and co-existing cardiovascular diseases has they have 
been shown to place patients with a transient ischemic attack (TIA) or minor ischemic 
stroke at an increased risk for a recurrent stroke.10,63,64 
In addition, age and race have been associated with an increased risk of stroke 
recurrence. We will account for age given research has demonstrated that those over the 
age of 60 years who have had a minor neurovascular event are at an increased risk of 
developing a recurrent stroke compared to those younger than 60 years old.1,2 In addition, 
a study suggests that Black individuals at higher risk of early stroke recurrence compared 
to White individuals (HR, 1.6; 95% CI, 1.1-2.3).65   
Although there is no difference in recurrent stroke in patients with a TIA or minor 
stroke between men and women as demonstrated by multiple studies, women score worse 
on the modified-Rankin Scale (mRS) 1 to 6 months after a TIA or ischemic stroke, 
implying women may be more disabled after the event.66  Therefore, we will account for 
gender given its potential influence on disability, one of our secondary outcomes. In 
addition, time from initial presentation to randomization, and number of TIA and minor 
ischemic stroke patients. To control for potential confounders, we will first randomize the 
patients and then perform a secondary analysis utilizing multiple logistic regression.  
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2.4 Review of Relevant Methods 
 
2.4.1 Study Design 
 
The trial will be a prospective, multi-center, randomized, double-blinded, placebo-
controlled trial performed to test the efficacy of vitamin E alpha-tocopherol in addition to 
clopidogrel and aspirin versus clopidogrel and aspirin alone in patients who have had a 
minor ischemic stroke or transient ischemic attack (TIA) who are at risk for a recurrent 
stroke. Similar to the trials that have investigated new treatment regimens for minor 
ischemic stroke and TIA patients, such as the CHANCE and POINT trial, this trial will 
mimic their study’s design.4,5 We will compare our intervention to the standard treatment 
to determine the efficacy of the new regimen. 
Multiple stroke centers will be selected using the NIH Stroke Net to increase the 
generalizability and reduce selection bias.67 Participants will undergo the typical 
neurological work-up according to the stroke center’s protocol. Once the patient meets the 
eligibility criteria and is enrolled into the study, they must obtain a magnetic resonance 
imaging (MRI) or computed tomography (CT), if not done already, within 24 hours of the 
index event with no evidence of hemorrhage or nonischemic cause of a neurological deficit 
as done in previous trials.4,5 Similar to the POINT trial, we will use an interactive, 
computer-based system, WebDCU, that will randomize patients in a 1:1 ratio to receive 
either DAPT plus vitamin E alpha-tocopherol supplements or DAPT plus placebo.4 Given 
current guidelines and results from the CHANCE trial, both groups will receive a 21-day 
course of both clopidogrel and aspirin followed by clopidogrel alone for the remainder of 
the 90 days to reduce the incidence of serious bleeding.5,21 Patients will receive either 
vitamin E alpha-tocopherol or placebo tablets for the full 90 days. Both participants and 
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researchers will be blinded to the intervention with the use of the assignment of a 
randomized identification number and the use of placebo tablets that will be identical to 
the alpha-tocopherol supplements.  
 
2.4.2 Control and Interventional Groups 
 
Participants will be randomized to either the control group, which will be dual 
antiplatelet therapy (DAPT) of clopidogrel and aspirin plus placebo tablets, or the 
interventional group, which will be DAPT plus 200IU vitamin E alpha-tocopherol 
supplements. Several studies have shown that DAPT is superior to other treatment 
regimens in reducing stroke recurrence in patients with a history of a high-risk transient 
ischemic attack (TIA) or minor ischemic stroke.4,5 We will mimic the procedures of the 
CHANCE trial and administer loading doses of 300mg oral clopidogrel and open label 
72mg to 300mg oral aspirin within 12 hours of the index event to both groups. Both groups 
will then receive 75mg aspirin per day from day 2 to day 21 and 75mg clopidogrel per day 
from day 2 to day 90. 5 In addition, the control group will receive a 90-day course of 
placebo supplements that resemble and taste like the vitamin E alpha-tocopherol 
supplements. 
The interventional group will receive 200IU of vitamin E alpha-tocopherol from 
day 1 to day 90 in addition to the DAPT.  It has not escaped us that 400IU is the most 
widely studied dose in vitamin E alpha-tocopherol trials. Controversy remains with studies 
suggesting no benefit of low dose 200IU alpha-tocopherol and no benefit of alpha-
tocopherol at higher doses platelets and oxidative stress.68,69 Studies have shown that 
vitamin E alpha-tocopherol increases nitric oxide and reduces platelet aggregation at doses 
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from 75IU/day to 200IU/day.70-73 Given the controversial research, risk of bleeding, and 
new antiplatelet regimen, we will utilize 200IU of alpha-tocopherol for 90 days. we 
hypothesize that this dose will be sufficient to potentiate aspirin in the first 30 days as well 
as provide antiplatelet and antioxidant characteristics in combination with clopidogrel to 
reduce the incidence of stroke recurrence within 90 days of the index event. 
 
2.4.3 Inclusion and Exclusion Criteria  
 
To determine the inclusion and exclusion criteria, we analyzed literature that 
studied the use of clopidogrel, aspirin, and alpha-tocopherol. By basing our inclusion and 
exclusion criteria on studies of all three drugs, we will encapsulate the full and adequate 
population that capture the population that may benefit from the intervention while 
minimizing adverse events. Specifically, we will be modeling our inclusion and exclusion 
criteria off of the CHANCE trial, POINT trial, and Leppalla et al study.4,5,50 Of note, we 
will exclude patients with a creatinine of greater than 2mg/dl or with hepatic insufficiency 
given hepatic metabolism and partial renal excretion of vitamin E, aspirin, and 
clopidogrel.74-76 The full inclusion and exclusion criteria can be found in Table 1. 
 
2.3.4 Primary Outcome 
The primary outcome that we will be measuring is stroke recurrence (ischemic and 
hemorrhagic) within 90 days of the index event. This outcome has been the main measure 
when trialing new therapies for a primary neurovascular event and will determine the 
effectiveness of the treatment regimen.5,27,30,77,78 Similar to the CHANCE trial, ischemic 
stroke will be defined as a sudden onset of new focal neurological deficit, evidence on 
imaging of an infarction for 24 hours or more, quick worsening of an existing focal 
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neurological symptom or sign, and not due to a nonischemic cause. Hemorrhagic stroke 
will be defined as blood in the parenchyma or subarachnoid space as confirmed on imaging 
with associated neurological signs or symptoms.5 Further analysis will be performed to 
analyze the incidence of ischemic stroke recurrence and hemorrhagic occurrence separately 
between the two groups. Though studies have measured this outcome as a time to 
recurrence, we will first measure it as a proportion.4,5,34 Secondary analysis will be 
performed to measure time to first recurrence using hazards ratio. This is further explained 
in section 3.10. 
 
2.3.5 Secondary Outcomes 
We will measure myocardial infarction (MI), all-cause mortality, degree of 
disability, and day 90 serum alpha-tocopherol levels as secondary outcomes. Previous 
studies have measured myocardial infarction as a primary or secondary outcome.4,5,79 A 
systemic review that analyzed 39 studies, including 65,996 patients, found that the annual 
risk for MI’s was 2.2%.80 In addition, a subgroup analysis of the CHANCE trial and found 
that 1.7% of the participants who were prescribed DAPT had a MI within 90 days of the 
initial event.62 The international POINT trial found only 0.4% of patients on DAPT had a 
MI within 90 days of the index event.4 Given the low percentage but its ischemic etiology 
and vitamin E’s potential antiplatelet role, MI will be measured as a secondary outcome. 
In addition, similar other studies, this trial will include 90-day all-cause mortality as a 
secondary outcome.4,5,30  
Other secondary outcomes include degree of disability (mRS) and serum alpha-
tocopherol levels. Degree of disability at 90 days will be measured using the modified 
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Rankin, a 6-leveled scale that evaluates recovery from a stroke and the patient’s level of 
disability, as seen in similar trials.5,81,82 A literature review analyzed 224 articles and found 
evidence to suggest that the mRS is reliable with strong test-re-test reliability (K=0.81 to 
0.95) and is valid when comparing the mRS score with the stroke type, lesion size, 
perfusion and impairment.83 We will assess the relationship between the degree of 
disability and the administration of vitamin E supplements in addition to DAPT. Multiple 
studies have shown that DAPT improves functional outcome, as measured by degree of 
disability, at 90 days when compared to aspirin.4,5,81 Lastly, we will measure  a fasting 
serum alpha-tocopherol level at the end of the 90 days and the mean serum alpha-
tocopherol level will be compared between groups. By doing so, we will determine if there 
is a significant difference in serum alpha-tocopherol and if a significantly higher or lower 
serum level can be associated with the primary or secondary outcomes as seen in other 
studies.53,84  
   
2.4.6 Safety Outcome 
 A meta-analysis, including 8 primary and secondary prevention trials, states that 
vitamin E increases the risk of hemorrhagic stroke (pooled relative risk 1.22; 95% CI, 1.00 
to 1.48; P=0.045) and reduces ischemic stroke risk by 10% (pooled relative risk 0.90; 95% 
CI, 0.82 to 0.99; P=0.02). The study suggests a significant relationship between 
hemorrhagic stroke and vitamin E; however, the confidence interval of the study includes 
1.00 and therefore, there may in fact be no relationship.85 A 2020 meta-analysis including 
18 randomized controlled trials, investigating primary and secondary prevention of stroke 
with the use of vitamin E supplements, demonstrated a significant risk reduction in 
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ischemic stroke (RR=0.92, 95% CI 0.85–0.99, p=0.04) but not in hemorrhagic stroke 
(RR=1.17, 95% CI 0.98–1.39, p=0.08). There was no significant difference in total stroke 
(RR= 0.98,95% CI 0.92–1.04, p=0.57).86 Stroke was not the primary outcome in multiple 
of the studies and the trial’s included also had varying populations with different co-
morbidities. Only half of the studies tested secondary prevention strategies for 
cardiovascular disease and many did not examine bleeding risk. As a precaution given the 
novel treatment and antiplatelet use, we will include hemorrhagic stroke in our primary 
outcome (in addition to ischemic stroke) and measure bleeding as a safety outcome. In 
addition, a data safety and review board will incrementally look at outcome data in order 
to identify if there is a statistical safety concern and determine if the trial should be halted.  
There was an increased risk in major bleeding in patients who had a minor ischemic 
stroke or a high-risk transient ischemic attack (TIA) and received aspirin and clopidogrel 
(DAPT) for 90 days compared to antiplatelet monotherapy of aspirin (0.9% vs 0.4%).4 
However, when a 21-day course of DAPT is prescribed followed by clopidogrel alone for 
the remainder of the 90 days, there was no significant increase in moderate or severe 
bleeding events compared to aspirin alone (0.3% vs 0.3%).5 As a result, the latter trial had 
a higher risk of secondary stroke of 8.2% compared to the first trial with a risk of 6.5%.4,5 
We propose that patients take a 21-day course of clopidogrel and aspirin followed by 
clopidogrel from day 22 to day 90. In addition, 200IU vitamin E alpha-tocopherol 
supplements, a mild antiplatelet, for the entirety of the 90 days as described in Section 
2.3.2. We will utilize the GUSTO criteria to define severe, moderate, and mild bleeding as 
used by the CHANCE trial and as described in Section 3.8.  
 
2.4.7 Sample Size Calculation 
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Our sample size was calculated using randomized controlled trials addressing 
stroke recurrence (hemorrhagic and ischemic) within 90 days of randomization. In the 
CHANCE trial, the recurrence risk for secondary stroke after a high-risk transient ischemic 
attack (TIA) (ABCD2  4) or minor ischemic stroke (NIHSS  3) was 8.2% associated 
with a 90-day course of clopidogrel and 21-day course of aspirin compared to 11.7% 
recurrence risk with aspirin alone (HR 0.68, 95% CI, 0.57 to 0.81, p<0.001). In the study’s 
interventional group, clopidogrel was given as a loading dose of 300mg on day 1 followed 
by 75mg daily from day 2 to day 90. Aspirin was given as a loading dose with an open 
label of 72mg to 300mg on day 1 followed by 75mg daily from day 2 to day 21. The 
limitation to this study is that the population was confined to China, limiting the 
generalizability of the study. Also, 6.4% of the sample size discontinued from the trial. 
However, the study was a large sample of over 5,000 participants and accounted for a 5% 
drop-out in its sample size. Because the study population and the interventional group in 
the CHANCE trial closely resembles this proposed trial’s control group, the 8.2% recurrent 
risk was used when calculating this study’s sample size.5 
To estimate the rate difference we were limited, due to the lack of research, to a 
small study that observed the relationship between the administration of aspirin and alp 
and recurrent stroke in patients with a history of a TIA (ABCD2  4) or a minor ischemic 
stroke (NIHSS  3) versus aspirin alone. 5.7% of patients who were given a 2-year regimen 
of 400IU vitamin E alpha-tocopherol plus aspirin had a recurrent stroke (hemorrhagic or 
ischemic) versus 12.5% in patients taking aspirin alone (p<0.05). A major limitation to this 
study is its analysis of only 50% of its small sample size of 100 participants because the 
trial was still ongoing and has not followed up with another publication with the full data. 
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In addition, it prescribed 375mg of Aspirin for 2 years instead of the new standard of 90-
day course of 75mg clopidogrel with 21-day course of 75mg of aspirin. Given the 
aforementioned study’s population and intervention, the addition of clopidogrel, and the 
POINT and CHANCE trial suggesting a 1.5-3.5% rate difference, the incidence of 5%, to 
create a 3.2% rate difference, was used when calculating the study’s sample size for this 
proposed trial.4,5,53 When calculating our sample size, we used a two-tailed alpha of 0.05 
and a power of 80% to detect a rate difference of 3.2%. We also took into account an 8% 
withdrawal rate. Please see Chapter 3 for the calculation.  
 
2.5 Conclusion 
 The literature previously described support the need for this randomized controlled 
trial. The proposed mechanism of vitamin E alpha-tocopherol and studies on its effects on 
platelet aggregation, aspirin potentiation, and antioxidant properties support vitamin E 
alpha-tocopherol’s potential role in preventing stroke recurrence in patients with a minor 
neurovascular event. However, the literature is limited in addressing this intervention in 
combination with clopidogrel and aspirin in this high-risk population. This study aims to 
fill this gap and improve clinical outcomes for patients with a moderate to high-risk TIA 
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CHAPTER 3: METHODS 
 
3.1 Study Design 
 
The study will involve multiple stroke centers including multiple emergency 
departments and neurology units that are responsible for discharging patients with a minor 
neurovascular event and giving prescriptions for outpatient medications. We will evaluate 
the effect of a 90-day regimen of 200IU vitamin E alpha-tocopherol supplements, in 
addition to the standard treatment of clopidogrel and aspirin, on stroke recurrence among 
patients who have had a moderate to high-risk TIA or a minor ischemic stroke. When a 
patient arrives to a study trial center and are determined to have a minor neurovascular 
event, they will be blindly randomized to the intervention or control group.   
 The primary null hypothesis of this randomized, double-blinded, multi-center, 
placebo-controlled trial is that patients with a moderate to high-risk TIA (ABCD2  4) or 
minor ischemic stroke (NIHSS  3) who receive a 90-day regimen of 200IU vitamin E 
alpha-tocopherol in addition to the treatment of clopidogrel and aspirin will not have a 
statistically significant difference in the proportion of stroke recurrence (hemorrhagic or 
ischemic) within 90 days from the primary neurovascular event. 
 
3.2 Study Sites, Population, & Sampling 
 
 The study population will include patients over the age of 18 years with a primary 
moderate to high-risk transient ischemic attack (TIA) (ABCD2  4) or minor ischemic 
stroke (NIHSS  3) who present within 12 hours to an emergency stroke center located 
within a tertiary medical center. The stroke center must be certified by the Joint 
Commission to contain the necessary training and resources for stroke patients. In 
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collaboration with the NIH Stroke Net, we will select stroke centers across the United 
States to participate in this interventional trial. We plan to include at least 10 stroke centers 
to recruit at least 2,002 participants over the course of a year. Each study site will have a 
physician investigator and research assistant who will remain in contact with the site’s 
emergency medicine physicians and neurologists who are primarily responsible for 
diagnosing and treating stroke patients to ensure enrollment of eligible patients. A clinical 
research coordinator (CRC) will also be put into place to oversee, direct and coordinate the 
clinical trial, ensuring that the protocols are met at each center. The CRC will also be 
responsible for ensuring resources are transported from the hub (Yale New Haven 
Hospital) to the satellite medical centers. The full research proposal will be submitted to 
the central Institutional Review Board (IRB) that is responsible for multi-center trials. Once 
the central IRB has accepted our proposal, we will begin recruiting eligible participants. 
 Participants must be at least 18 years old and have either a TIA with an ABCD2 
score of 4 or greater or a minor, nondisabling, ischemic stroke with a NIHSS score of 3 or 
less at the time of randomization. Patients who experience a TIA must have resolution of 
neurological symptoms at the time of randomization. A head computed tomography (CT) 
scan, CT angiography, magnetic resonance imaging (MRI), or MR angiography scan must 
be obtained and demonstrate that the neurological symptoms are NOT due to a hemorrhage 
or another brain pathology such as a tumor or vascular malformation as recommended by 
American Heart Association guidelines.1 If the inclusion and exclusion criteria are met, all 
participants must sign and date a consent form (Appendix A) in order to be included and 
randomized to the trial. Please see Table 1 for the extensive exclusion criteria and a review 
of the inclusion criteria. 
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Table 1. Inclusion and Exclusion Criteria   
Inclusion Criteria Exclusion Criteria 
1. Age ≥ 18 years old 
2. Acute, minor, nondisabling stroke with a 
NIHSS ≤ 3 at time of randomization 
3. TIA with resolution of symptoms by the time 
of randomization and a moderate-high risk of 
stroke recurrence as classified by an ABCD2 
score ≥ 4  
4. Head CT or MRI showing no evidence of a 
hemorrhage or other brain pathology that could 
contraindicate treatment or explain 
neurological deficits (i.e., tumor, vascular 
malformation, abscess, multiple sclerosis)  
5. Must be randomized within 12 hours of 
symptom onset 
6. Signed and dated informed consent 
1. Age ≤ 18 years old 
2. TIA symptoms limited to isolated numbness, visual changes, or 
dizziness/vertigo 
3. Candidate for thrombolysis, endarterectomy, or endovascular 
intervention as determined by providing physician (unless patient 
refuses the intervention by time of randomization) 
4. Received intravenous or intra-arterial thrombolysis within 1 week of 
primary event 
5. Major surgery within 3 months prior to the primary event 
6. GI bleed within 3 months prior to primary event 
7. Clear indication for anticoagulation therapy or anticipation to treat 
during study period  
8. Ischemic event due to angiography or surgery 
9. Non-cardiovascular comorbidity with life expectancy of ≤ 3 months 
10. Score of more than 2 on the modified Rankin scale immediately before 
occurrence of the primary ischemic stroke or TIA 
11. Contraindication to clopidogrel or aspirin (known allergy, serum Cr 
>2 mg/dL, hepatic insufficiency, severe cardiac failure, hemostatic 
disorder, systemic bleeding, history of thrombocytopenia or 
neutropenia, current thrombocytopenia platelet count <100x109, 
current neutropenia <1x109/l, history of drug-induced hematologic or 
hepatic abnormalities) 
12. Anticipated requirement for long-term non-study antiplatelets or 
NSAIDs affecting function of platelets 
13. Currently receiving an investigational therapy or treatment within the 
last 7 days 
14. Other neurological complications that complicate assessment of 
outcomes 
15. Premenopausal or postmenopausal women at risk for pregnancy 
within 12 months of last menses without a negative pregnancy test or 
without reliable contraception 
16. Unwilling or unable to discontinue concomitant medications 
17. Unavailable for follow-up 
18. Missing signed and dated informed consent 
19. No use of individual supplements of vitamin A, E or beta carotene for 
more than once a week 
 
3.3 Participant Confidentiality 
 
 This multi-center trial must be reviewed and approved by the Central Institutional 
Review Board (central IRB) prior to study initiation. In addition, all research members 
must be certified through the Health Insurance Portability and Accountability Act (HIPAA) 
before recruitment begins. For patient privacy, patient records and data will be secured 
through device encryption and password protected data. The information will only be 
accessible to members of the research team. In addition, we will de-identify all participants 
and utilize a computerized program that will randomize participants to identification 
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numbers. After we complete data analyses, all participant data and information will be 
properly disposed.  
 After the participant has met the inclusion and exclusion criteria, then he or she will 
be required to complete written, informed consent (Appendix A). A research assistant at 
each clinical site will explain the consent form and ensure that each participant has signed 
and dated the form prior to randomization. The consent form will include a detailed 
description of the trial, potential risks and benefits, economic considerations, and 
confidentiality. The form will also state that participants have the ability to withdraw from 
the trial at any point. Once written, informed consent is obtained, the participant will be 
randomized into the trial. 
 
3.4 Study Variables 
 
The independent variable will be 200IU vitamin E alpha-tocopherol supplements 
that will be delivered in oral capsules. The control variable will be oral placebo tablets that 
will have the same packaging and be identical to the taste and appearance of the alpha-
tocopherol supplements. The primary outcome will be stroke recurrence (hemorrhagic or 
ischemic), including fatal and non-fatal events, within 90 days of randomization. An 
ischemic stroke is defined as an acute, arterial block reducing or halting blood flow to the 
brain resulting in focal symptoms. Hemorrhagic stroke is defined as extravasation of blood 
into the parenchymal or subarachnoid space of the brain. The safety outcome will be 
moderate and major bleeding as defined by the GUSTO criteria described in Table 4. 
 The secondary dependent variables that will be measured are degree of disability, 
serum vitamin E alpha-tocopherol, proportion of myocardial infarction (MI), and 
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proportion of all-cause mortality. Degree of disability will be measured in all participants 
using the modified Rankin Scale (mRS) at the time of randomization and at the end of 90 
days. Vitamin E alpha-tocopherol level is defined as the concentration of alpha-tocopherol 
within the patient’s serum. The reference range for alpha-tocopherol is defined as 5.5-17.0 
mg/L in people 18 years or older. MI, with or without coronary revascularization, will be 
defined as myocardial necrosis with myocardial ischemia and we will use the Universal 
Definition of Myocardial Infarction algorithm that accounts for cardiac biomarkers, EKG 
abnormalities, imaging, pathology, and clinical setting.2 All-cause mortality will be defined 
as all participant deaths that occur within 90 days of randomization. 
Table 2. Baseline Characteristics Description and Analysis 
Baseline Characteristics Description Analysis  
Age  Measured in years ANOVA 
Female Sex No./total No.(%) Chi-Square 
Body Mass Index  Median (Range) ANOVA 
Race White, Black, Asian, Hispanic, Other (No./total No.(%)) Chi-Square 
Ischemic Heart Disease No./total No.(%) Chi-Square 
Hypertension No./total No.(%) Chi-Square 
Diabetes Mellitus No./total No.(%) Chi-Square 
Smoking Pack Years (# cigarettes per day) x (years smoked): Mean Pack Years ± 
SD 
ANOVA 
Clopidogrel Use at Presentation No./total No.(%) Chi-Square 
Aspirin Use at Presentation No./total No.(%) Chi-Square 
Time from Initial Presentation to Randomization Mean time (hrs) ± SD ANOVA 
ABCD2 Score Median (Range) ANOVA 
NIHSS Score Median (Range) ANOVA 
TIA Subjects No./total No.(%) Chi-Square 
Minor Ischemic Stroke Patients No./total No.(%) Chi-Square 
  
Stroke recurrence within 90 days of the neurovascular event can be attributed to 
many baseline characteristics and have the potential to impact the study groups. We will 
control for many factors including age, gender, body mass index, race, known risk factors 
(ischemic heart disease, hypertension, diabetes mellitus, smoking history), medication use 
at presentation (aspirin, clopidogrel, multivitamin use), time from initial presentation to 
randomization, neurovascular event (TIA vs minor ischemic stroke), and median 
qualifying neurologic score (ABCD2, NIHSS). A baseline evaluation will occur at the time 
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of randomization after the patient meets the inclusion criteria. Statistically significant 
differences in baseline characteristics found between study groups will be controlled for 
using the multiple logistic analysis approach. Please refer to Table 2 for description and 




3.5.1 Group Randomization & Blinding 
 
 Participants who enter the stroke centers who meet the inclusion and exclusion 
criteria will be randomized in a 1:1 ratio to either the interventional (vitamin E alpha-
tocopherol plus standard treatment) or control (standard treatment alone) group. This 
randomization will be performed using a computerized program. Trained users will use the 
computerized program to complete an eligibility checklist. If the program finds that the 
patient is eligible then the patient will be enrolled and assigned to a randomization number. 
Participants, research assistants, and physician investigator at every study site will be 
blinded to the group assignment. All participants in both groups will be given the same 
instructions on the use, benefits, and risks of the medications. Research assistants and 
physician investigators will also be blinded to the primary, secondary, and safety outcome. 
The clinical coordinator center located at the hub of the trial will be responsible for creating 
and distributing study packets with either the placebo or the vitamin E tablet. The pharmacy 
at each study site will assist in this process by ensuring that the placebo pills are identical 
to the vitamin E alpha-tocopherol pills in appearance and taste. This method will allow for 
standardization of delivery as well as ensuring that the participants, research assistants and 
physician investigator are blinded to the intervention the participant receives at each study 
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center. If any complications arise and the participant or provider needs to be un-blinded, 
the clinical research coordinator may be contacted to identify what the participant received. 
 
3.5.2 Intervention Design 
 
 Participants in the interventional group will receive clopidogrel and aspirin plus 
vitamin E alpha-tocopherol. The initial loading dose on day 1 will include 3 oral tablets: 
300mg clopidogrel, open label 72mg-300mg aspirin, and 200IU alpha-tocopherol. The 
aspirin loading dose will be determined by the primary physician. All three medications 
must be given within 12 hours of the primary event. The participants will receive a 20-day 
supply of 75mg clopidogrel, 20-day supply of 200IU alpha-tocopherol, and 20-day supply 
of 75mg aspirin. Patient’s will take one oral tablet of clopidogrel, alpha-tocopherol, and 
aspirin by mouth once daily in the evening after eating a meal from day 2 to day 21. From 
day 21 to day 90 study participants will discontinue the aspirin and continue protocol for 
alpha-tocopherol and clopidogrel. Patient’s will receive a refill for clopidogrel and alpha-
tocopherol at the follow-up appointments to encourage adherence. 
 
3.5.3 Control Design 
 
 Participants in the control group will receive the standard treatment of clopidogrel 
and aspirin plus placebo. The initial loading dose on day 1 will include 3 oral tablets: 
300mg clopidogrel, open label 72mg-300mg aspirin, and a placebo tablet identical to that 
of alpha-tocopherol. The aspirin loading dose will be determined by the primary physician. 
All three medications must be given within 12 hours of the primary event. The participants 
will receive a 20-day supply of 75mg clopidogrel, 20-day supply of placebo, and 20-day 
supply of 75mg aspirin. Patient’s will take one oral  tablet of clopidogrel, placebo, and 
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aspirin by mouth once daily in the evening after eating a meal from day 2 to day 21. From 
day 21 to day 90 study participants will discontinue the aspirin and continue the same 
protocol for the placebo and clopidogrel. Patient’s will receive a refill for clopidogrel and 
placebo at the follow-up appointments to encourage adherence. 
 
3.5.4 Other Considerations 
 
 If the patient has yet to take the loading dose of 300mg clopidogrel and open label 
72mg-300mg aspirin, then they will take it in conjunction with the alpha-tocopherol or 
placebo supplement. If the patient has already received the clopidogrel, aspirin, or both, at 
the time of randomization then they will take the alpha-tocopherol or placebo tablet 
alongside the missing medication or alone. Patients should receive the oral vitamin E 
supplements within 12 hours of the primary event. Participants who are admitted to the 
hospital will be provided the daily oral vitamin E alpha-tocopherol supplements alongside 
the clopidogrel or aspirin by their providing physician. When participants are discharged, 
they will be instructed on the use of vitamin E alpha-tocopherol supplements. Instructions 
will remain consistent among both the interventional and control groups. 
 
3.6 Data Collection 
 
 The baseline characteristics described in Table 2 will be recorded at the time of 
randomization by blinded researchers using the form found in Appendix B. Time will be 
allocated to training research assistants on how to survey, utilize stroke scales, document 
patient data, interpret laboratory values, and interpret radiologist neuroimaging results.  
 Stroke recurrence (hemorrhagic or ischemic) is the primary outcome and will be 
measured utilizing a stroke free questionnaire (Appendix F) imaging. The patient will 
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undergo either a head computerized tomography (CT) scan or a magnetic resonance image 
(MRI) scan that will be read by a neuroradiologist who will determine if there are signs of 
an ischemic or hemorrhagic stroke. Imaging will be performed when symptoms arise 
within 90 days of randomization or at the end of the trial at day 90. Patients will have 
imaging done at the time of randomization to determine patient’s current stroke status and 
a baseline image to compare future CT/MRI results.  
 The secondary outcome of change in disability will be measured at time of 
randomization and at the end of the 90 days. Disability will be measured using the six 
leveled modified Rankin Scale (mRS).3 Research assistants will be trained and given 
Appendix D to determine the disability of each participant in both arms. Once the study is 
complete, the mean change of disability within each group will be determined. The mean 
change of disability between groups will then be analyzed. 
 In order to determine serum vitamin E alpha-tocopherol levels, we will collect 
whole blood via peripheral blood draws at the end of the 3 months of each participant. For 
accurate results, all participants must be fasting for 12-hours prior to the blood draw. Serum 
alpha-tocopherol levels will be determined by using high-performance liquid 
chromatography. The blood specimen will be collected in a red top tube and will be placed 
in an amber vial to protect from light. If the specimen is unable to be analyzed within 7-
days then the specimen must be refrigerated or frozen and analyzed within 44 days. If the 
blood specimen is grossly hemolyzed or has gross lipemia then it will be rejected. The 
mean day 90 serum alpha-tocopherol levels will be compared between groups.  
 Myocardial infarction (MI), including fatal and non-fatal events, will be determined 
by the providing physician who will use the Universal Definition of Myocardial Infarction 
 52 
algorithm that takes into account cardiac biomarkers, EKG abnormalities, imaging, 
pathology, and clinical setting.2 When a patient presents with signs or symptoms of a MI 
or there is a clinical suspicion by the provider, patients will undergo the standard testing.  
 Blinded research assistants will follow up with study participants at day 7 from 
randomization to document verbal compliance and address any issues or concerns with 
medication use or effects. The study participants will then have an appointment with a 
blinded clinician at day 21 to ensure withdrawal of aspirin, continuation of vitamin E alpha-
tocopherol and clopidogrel.  At day 90 the study participants will have an in-person 
appointment where trained blinded research assistants will measure the modified Rankin 
Scale (mRS) score and the National Institute of Health Stroke Scale score as described in 
Appendix D and E, respectively. At each visit, the participants will be questioned on stroke 
recurrence since randomization and will be assessed for any stroke symptoms or signs 
using the Questionnaire for Verifying Stroke-Free Status (QVSFS) detailed in Appendix 
F.4 We will also ask about myocardial infarction events within the past 90 days. We will 
also use patient medical and death records to support the measurement of our outcomes, 
including all-cause mortality. 
 
3.7 Adherence  
 
Participants will be closely monitored throughout the trial. At day 7, 21 and 60, the 
participants will have a follow up appointment with the clinicians. At the time of follow-
up, they will receive a refill of the clopidogrel, aspirin, and alpha-tocopherol (or placebo) 
supplements. At the appointment, participants will be asked if they have been adherent to 
the medication using the Morisky scale. Patients will be considered adherent if they report 
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at least moderate compliance. The inability to adhere to the medication will disqualify the 
patient from participating in the trial.  
Table 3: Proposed Trial Design Influenced by CHANCE and POINT trial5,6 
Measurements Baseline/Screening/ 










Eligibility X      
Signed Consent 
Form 
X      




X      
ABCD2 Score (for 
TIA) 
X      
Modified Rankin 
Scale (mRS) 
    X X 
NIHSS Score X    X X 
Vital Signs X     X 
Basic Labs (CBC, 
CMP) 
X    X X 
Serum Alpha-
Tocopherol Level 
    X X 
Head CT/MRI X    X X 
EKG X    X X 
Current 
Medications 
X X X X X X 
Stroke Free 
Questionnaire 




 X X X X  
Medication Refill   X X   
 
3.8 Monitoring for Adverse Events 
 
 An adverse event is defined as an unexpected medical occurrence that happens 
during pharmaceutical treatment. We will submit a data and safety monitoring plan that 
will go into detail about collecting adverse events that will be performed by the clinical 
research coordinator (CRC). A data monitoring center will be utilized to monitor all such 
events throughout the trial. Participants will be closely monitored for any adverse events 
throughout the entirety of the trial. All events will be documented, reported and included 
in a final clinical study report. As a safety outcome, severe or moderate bleeding will be 
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monitored for.  If an adverse event occurs, the CRC may be contacted to unblind the 
participant, research investigator, and primary physician to the intervention. Serious 
adverse events will be reported to the IRB immediately. If bleeding occurs, then patients 
will be instructed to stop the alpha-tocopherol tablets. In cases of serious active bleeding 
and prolonged prothrombin time, vitamin K supplementation may be considered by the 
primary physician.7  
Table 4: GUSTO Criteria8  
 
Severe Bleeding 
Intracranial hemorrhage or bleeding causing hemodynamic compromise requiring blood or fluids, inotropic 
support to maintain blood pressure, surgical intervention (other than bleeding site repair), ventricular assist 
devices or CPR to maintain cardiac output. 
Moderate Bleeding Bleeding requiring blood transfusions but does not cause hemodynamic compromise.  
Mild Bleeding Bleeding that does not require transfusions nor cause hemodynamic compromise. 
 
 
3.9 Sample Size Calculation 
 
Our study aims to determine the difference in stroke recurrence among patients who 
have a moderate to high-risk transient ischemic attack or minor ischemic stroke who 
receive 200IU vitamin E alpha-tocopherol in addition to the standard treatment versus 
those who receive the standard treatment alone. Taking into consideration the literature 
discussed in the sample size literature review and using the Power and Precision software 
(Appendix G), we determined that this trial will require at least 2,002 participants, with 
1,001 participants per arm, in order to provide 80% power to detect a rate difference of 
3.2% in the vitamin E alpha-tocopherol group, with a two-sided type I error of 0.05 and an 








The statistical data will be analyzed using the intention-to-treat protocol by blinded 
researchers. The statistical significance will be defined by a p-value less than 0.05. Our 
dichotomous, primary outcome of stroke recurrence within 90 days will be measured as a 
proportion in the control and intervention group. Therefore, the primary outcome will be 
compared between groups using a chi-squared test. Because baseline characteristics and 
other confounding variables may be associated with the dependent variable, multiple 
logistic regression will be performed after the initial data analysis. To determine baseline 
characteristic variation between the study arms, we will compare each variable using the 
appropriate statistical analysis as suggested in Table 2.  
 Secondary outcomes include mean change in disability, mean serum vitamin E 
alpha-tocopherol, proportion of myocardial infarction (MI), and proportion of all-cause 
mortality. Mean change in disability, as measured by the mRS scale, from baseline to day 
90 will be compared between groups using student’s t-test. Mean serum vitamin E alpha-
tocopherol at day 90 will be compared between groups using student’s t-test. Proportion of 
MI and all-cause mortality will both be compared between groups using chi-square 
analysis. 
We will analyze our data as a time to stroke recurrence using the Kaplan-Meier 
survival analysis as a secondary analysis to investigate risk of stroke recurrence at different 
time points. We will then use Cox proportional hazards regression to account for 
confounding variables. We are confident in utilizing this analysis as a secondary approach 
after calculating that only a few hundred participants are needed for this survival analysis. 
This participant count is less than our proposed 2,002 participants. 
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3.11 Timeline  
 
 The estimated total duration of the recruitment and data collection will be 32 
months. The pre-enrollment phase will take approximately 6 months and will include 
attaining central IRB approval, preparing and distributing the vitamin E alpha-tocopherol 
to all study sites, and training research assistants at each study site how to survey, utilize 
stroke scales, document patient data, interpret laboratory values, and interpret 
neuroimaging results. We will allocate 20 months towards continuous enrollment and 
follow-up. After halting recruitment, an additional 3 months will be given towards follow-
up completion. Final data analysis will take approximately 6 months.  
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 We anticipate this trial to possess many strengths. First, the trial is novel in 
investigating alpha-tocopherol’s proposed mechanism, in addition to dual antiplatelet 
therapy (DAPT) of clopidogrel and aspirin, and the regimen’s potential efficacy in reducing 
the proportion of stroke recurrence in patients with a transient ischemic attack (TIA) or 
minor ischemic stroke compared to DAPT alone. The prospective study design allows for 
the collection of specific data in real time unlike retrospective trials that are more prone to 
biases and confounders. To increase the internal validity of the trial, we will implement a 
strict randomization process, blind the participants and researchers, and have a placebo 
group. Randomizing patients to either the control or interventional group utilizing a 
computer-based program will aid in reducing selection bias and producing comparable 
groups with respect to baseline characteristics. In addition, this trial will be double-blinded, 
with the use of a randomized identification number and identical placebo supplement, to 
reduce observer and confirmation bias. By increasing the validity of this trial, we will be 
able to establish a relationship between vitamin E alpha-tocopherol and stroke recurrence. 
We will also increase the external validity by having a multi-center trial design. Utilizing 
the NIH Stroke Net, we will randomly select multiple stroke centers throughout the United 
States to increase the generalizability of the trial.  
 
4.2 Limitations 
 We anticipate our randomized, multi-center, double-blinded trial to have many 
strengths, but also have a few limitations. First, we will be including only stroke centers 
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within tertiary medical centers. While these hospitals treat the majority of stroke patients, 
the study may not be generalizable to patients in more rural settings who lack the access to 
tertiary medical centers and are treated primarily at rural hospitals. However, because the 
majority of patients are treated at stroke centers that have the appropriate training and 
resources, we feel that the inclusion of only these certified centers is the appropriate step 
in determining a new treatment regimen to reduce the risk of stroke recurrence in patients 
who experience a minor neurovascular event.  
Another potential issue is the trial’s inability to enroll around the clock leading to 
a possible convenient sample causing a potential selection bias and limiting the 
generalizability of the study. Selection bias may also occur through the loss to follow up. 
The trial is also at risk of information bias; however, we will attempt to reduce this with 
the use of standard questionnaires, measurements and imaging results. We also will have 
an extensive exclusion criterion that will exclude patients with a cardioembolic or 
hemorrhagic stroke, mild TIA, moderate or severe ischemic stroke, hepatic insufficiency, 
renal disease, and cardiac failure. Therefore, the sample size may not fully encompass all 
stroke patients who are risk for a recurrent stroke. In addition, patients may have varying 
vitamin E diet’s that may contribute to stroke recurrence and alter the levels of their serum 
alpha-tocopherol levels. However, to accurately measure serum alpha-tocopherol levels, 
the participant must be fasting for 12 hours prior to the blood draw. However, after our 
primary analysis, we will perform secondary analysis of both multiple logistic regression 
and cox-proportional hazards regression to control for confounding variables. 
Given the trial’s novelty in delivering vitamin E alpha-tocopherol supplements in 
addition to DAPT to stroke patients, we will administer a low dose of 200IU of alpha-
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tocopherol to reduce the risk of adverse effects, such as major bleeding, that may be seen 
with higher dosing of 400IU, despite its positive results in the literature. If the addition of 
200IU alpha-tocopherol does not result in an increased risk of moderate or major bleeding 
then future directions could include an adaptive study design that could examine the effects 
of different doses of vitamin E alpha-tocopherol with the use of a larger sample size. 
 
4.3 Clinical Significance 
 
Reducing the incidence of recurrent strokes would lessen the burden that exists for 
healthcare professionals, including physician assistants, and reduce resource usage in 
emergency departments and neurology units. According to the American Heart Association 
statistics, stroke has a large healthcare burden with 800,000 strokes yearly, costing 
approximately $34 billion a year.1 About 25% of these yearly strokes are recurrent, 
suggesting an estimated cost of over $8.5 billion.1 Not only does stroke recurrence take a 
toll on the healthcare system, but, more importantly, on the individual. According to a 
study, a patient’s healthcare bill totals to $34,639 following discharge of a recurrent, non-
cardioembolic ischemic stroke. This is significantly higher than the $25,036 that is spent 
for a new stroke occurrence.2 If we reduce the incidence of recurrent ischemic strokes in 
this vulnerable population then their quality of life can be improved with a decrease in 





1. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 
Update: A Report From the American Heart Association. Circulation. 
2019;139(10):e56-e528. 
2. Engel-Nitz NM, Sander SD, Harley C, Rey GG, Shah H. Costs and outcomes of 







Appendix A: Consent Form 
 
Adapted from Consent for Participation in a Research Project, 200 FR.1 (2016-2) 
YALE UNIVERSITY SCHOOL OF MEDICINE 
 
Study Title: VITAMIN E ALPHA-TOCOPHEROLS TO PREVENT RECURRENT 
STROKE IN PATIENTS WITH A MINOR NEUROVASCULAR EVENT 
 
Principal Investigator: Charles Wira, MD 
 
Invitation to Participate and Description of Project 
 
You are invited to participate in a research study that is designed to look at the treatment 
options for patients who have a transient ischemic attack (TIA) or minor ischemic stroke. 
This study will specifically look at the addition of vitamin E supplements to the current 
treatment regimen. You have been asked to participate in this study because you have 
recently been diagnosed with a moderate to high-risk TIA or a minor stroke and are at high 
risk for stroke recurrence. 
 
In order to decide whether or not you wish to be a part of this research study, you should 
know enough about the study’s risks and benefits to make an informed decision. This 
consent form gives you detailed information about the research study, which a member of 
the research team will discuss with you. This discussion should go over all aspects of this 
research: the purpose, the procedures that will be performed, any risks of the procedures, 
possible benefits and possible alternative treatments. Once you understand the study, you 
will be asked if you wish to participate; if so, you will be asked to sign this form. 
 
Description of Procedures 
 
If you agree to participate in this study, you will be asked various questions regarding your 
baseline characteristics including your age, gender, race, and past medical history. If you 
have not had one already as part of your workup, you will undergo a computed tomography 
(CT) scan or magnetic resonance imaging (MRI) prior to initiation to determine any 
ischemic damage or presence of bleeding. A research assistant will then utilize a computer 
system that will assign you to receive either vitamin E alpha-tocopherol supplements or 
placebo pills (a pill causing no therapeutic benefit or harm) for a total of 90 days. In 
addition, you will be assigned a unique identification number. Randomization through this 
computer-based program ensures an equal chance for all participants to be assigned to 
either group. The supplements will be taken as an adjunct to your dual antiplatelet treatment 
of clopidogrel and aspirin.  
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Once you are determined to have a minor ischemic stroke or a transient ischemic attack, 
you will receive a loading dose of 300mg clopidogrel, 72mg-300mg aspirin (as determined 
by the provider), and either 200IU vitamin E alpha-tocopherol or a placebo pill. You will 
then be prescribed a 20-day course of 75mg clopidogrel and 75mg aspirin taken once daily 
from day 2 to day 21. From day 22 to day 90, you will continue to take clopidogrel once 
daily. From day 2 to day 90, you will be prescribed either 200IU vitamin E alpha-
tocopherol or placebo supplements to be taken once daily. All medications should be taken 
in the evening, together, with a meal. The treatments will be given as a monthly supply and 
will be administered at the time of randomization. Your medication will be refilled at your 
follow-up appointments.  
 
- DAY 1 you will receive: 
o 300mg clopidogrel 
o 72mg-300mg aspirin (dose determined by provider) 
o 200IU vitamin E alpha-tocopherol OR placebo 
- DAY 2 to DAY 21 
o 75mg clopidogrel 
o 75mg aspirin 
o 200IU vitamin E alpha-tocopherol OR placebo 
- DAY 22 to DAY 90  
o 75mg clopidogrel 
o 200IU vitamin E alpha-tocopherol OR placebo 
 
You will be contacted via telephone for follow-up on days 7, 21, and 60 from time of 
randomization. The follow-up appointments will include a questionnaire to assess for signs 
and symptoms of a stroke and receive your medication refill. The study will conclude on 
day 90 after your in-person appointment. At this appointment, you will undergo an MRI 
and a questionnaire to assess for stroke recurrence. After the study is complete, we 
recommend follow-up with your neurologist to determine next steps in your treatment plan. 
A description of this study will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, 
the Web site will include a summary of this results. You can search this Web site at any 
time. 
You will be told of any significant findings that are developed during the course of your 
participation in this study that may affect your willingness to continue to participate. 
Research results will not be returned to your doctor. If research results are published, your 
name and other personal information will not be given. 
Risks & Inconveniences 
 
Participation in this trial may place you at an increased risk of bleeding. Antiplatelet drugs, 
including clopidogrel, aspirin, and vitamin E, are blood thinners that prevent blood cells 
from clumping together to form a clot. Therefore, the addition of vitamin E to the standard 
regimen may increase your risk of bleeding. Patient’s more commonly experience minor 
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bleeding such as bruising easily or prolonged bleeding from minor cuts. However, though 
rare, bleeding may occur in the brain, gastrointestinal tract, nosebleeds, eyes, etc. Bleeding 
may require hospitalization, blood transfusions and cause fatality. If signs and/or symptoms 
arise, you should go to the nearest hospital to be assessed and undergo diagnostic measures. 
If bleeding occurs, this will be considered an adverse event and you may be withdrawn 
from the study. 
 
You may also experience other side effects related to the three medications. These side 
effects include weakness, dizziness, nausea, abdominal pain, diarrhea, constipation and 
other possible side effects listed on the label of each medication. 
 
You will also receive exposure to radiation through computed tomography (CT) and/or 
magnetic resonance imaging (MRI) as standard diagnostic measures for a stroke or 
transient ischemic attack. A CT scan or MRI is required prior to randomization. Imaging 
will aid in your diagnosis and in ruling out other possible causes of your symptoms and/or 
signs such as brain bleeding, tumors, etc. At the end of the study, you will undergo an MRI 




The results of this study may help the medical community in determining the most effective 
treatment regimen for secondary prevention of recurrent strokes. A potential benefit of 
taking vitamin E alpha-tocopherol supplements in addition to the clopidogrel and aspirin 
is reducing the risk of recurrent strokes within 90 days of having a minor ischemic stroke 
or transient ischemic attack. Reducing the risk of recurrent stroke may increase quality of 
life and reduce disability severity. 
 
Economic Considerations  
 
Participation in this study is voluntary. No direct compensation will be given for 
participation in this trial. You will be reimbursed for the vitamin E supplements, placebo 
supplements, serum alpha-tocopherol blood draws, and other non-standard of care 
procedures. If you are injured or become ill while on the study, seek immediate treatment 
and contact the study doctor. If your illness is due to the study drug, vitamin E, you will 
not be financially responsible. You will receive a parking voucher for your day 90 in-




The alternative is to deny participation in this study. If you decline participation into this 
study then your primary medical provider will provide you your treatment plan for the 







Information about your study participation will be entered into your Electronic Medical 
Record (EMR). Once placed in your EMR, these results are accessible to all of your 
providers who are appropriate to have access to your EMR (e.g., health insurance company, 
disability provider.) The protected information that will be collected in this study includes 
demographics, medical history, physical examinations, routine lab tests, current 
medications, vital signs, CT/MRI results, and information recorded in study questionnaires.  
 
Information about you and your health which might identify you may be used or given to: 
• The U.S. Department of Health and Human Services (DHHS) agencies  
• Representatives from Yale University and the Human Investigation Committee 
(the committee or Institutional Review Board that reviews, approves, and 
monitors research on human subjects), who are responsible for ensuring research 
compliance. These individuals are required to keep all information confidential  
• Your providers who are participants in the Electronic Medical Record (EMR) 
system  
• Those individuals at Yale who are responsible for the financial oversight of 
research including billings and payments  
• The study doctor, Dr. Charles Wira, and the Yale study team  
• The U.S. Food and Drug Administration (FDA). This is done so that the FDA can 
review information about the new drug product involved in this research. The 
information may also be used to meet the reporting requirements of drug 
regulatory agencies.  
• The study sponsor or manufacturer of study drug and/ or their representatives  
• Health care providers who provide services to you in connection with this study.  
• Laboratories and other individuals and organizations that analyze your health 
information in connection with this study, according to the study plan.  
• Data and Safety Monitoring Boards and others authorized to monitor the conduct 
of the Study  
Any identifiable information that is obtained in connection with the study will remain 
confidential and will be disclosed only with your permission or as required by the U.S. or 
State law. Examples of information that we are legally required to disclose include abuse 
of a child or elderly person, or certain reportable diseases. Study data will be kept 
confidential through the use of encrypted servers and locked cabinets. When the results are 
of the research are published or discussed in conferences, no information will be included 
that would reveal your identity unless your specific consent for this activity is obtained. 
 
All healthcare providers subject to HIPAA (Health Insurance Portability and 
Accountability Act) are required to protect the privacy of your information. The research 
staff at the Yale School of Medicine are required to comply with HIPAA and to ensure the 
confidentiality of your information. Some of the individuals or agencies listed above may 
not be subject to HIPAA and therefore may not be required to provide the same type of 
confidentiality protection. They could use or disclose your information in ways not 
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mentioned in this form. However, to better protect your health information, agreements are 
in place with these individuals and/or companies that require that they keep your 
information confidential.  
 
By signing this form, you authorize the use and/or disclosure of the information described 
above for this research study. The purpose of the uses and disclosures you are authorizing 
is to ensure that the information relating to this research is available to all parties who may 
need it for research purposes.  
 
Voluntary Participation & Withdrawal 
 
Participating in this study is voluntary. You are free to choose deny participation in this 
study. Refusing to participate will involve no penalty or loss of benefits to which you are 
otherwise entitled (such as your health care outside this study, the payment for your health 
care, and your health care benefits). However, you will not be able to enroll in this research 
study and will not receive study procedures as a study participant if you do not allow use 
of your information as part of this study. 
 
If you do become a subject, you are free to stop and withdraw from this study at any time 
during its course. To withdraw from this study, you can call a member of the research team 
at any time and tell them you no longer want to take part. This will cancel any future 
appointments. The researchers may withdraw you from participating in the research if 
necessary. You may be withdrawn if necessary. You may be withdrawn if you have a 
serious side-effect related to vitamin E alpha-tocopherol such as moderate or major 
bleeding events. You may also be withdrawn from the study if you do not adhere to the 
treatment.  
 
Withdrawing from the study at any time will involve no penalty or loss of benefits to which 
you are entitled. Withdrawing will also not harm your relationship with your providers or 
interfere with receiving standard treatment from your providers, if requested. When you 
are withdrawn from the study, no new health information identifying you will be gathered 
after that date. Information that has already been gathered may still be used and given to 
others until the end of the research study, as necessary to ensure the integrity of the study 




We have used some technical terms in this form. Please feel free to ask about anything you 
don’t understand and to consider this research and the permission from carefully – as long 










I have read (or someone has read to me) this form and have decided to participate in the 
project described above. In general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction. My signature 
also indicates that I have received a copy of this consent form. 
 
________________________________ 
Name of Subject 
 
________________________________             _____________ 
Signature                 Date 
 
 
________________________________              _____________ 
Signature of Person Obtaining Consent             Date 
 
 
If you have any further questions about this project or if you have a research related 
problem, you may contact the co-investigator Veronica Guirguis at 
veronica.guirguis@yale.edu. 
 
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at (203) 432-5919. If you would like to talk with 
someone other than the researchers to discuss problems, concerns and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 
contact the Yale Human Investigation Committee at (203) 785-4688. 
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Appendix B: Baseline Characteristics Survey 
 
 
Participant Number: __________________    Research Assistant: ___________________ 
 
Research Center: _____________________           Date: ____________ 
 














Ischemic Heart Disease _____ 
 
Diabetes Mellitus _____ 
 
Smoking History  
 If yes:  Current? Former? 
 How many cigarettes a day? 
 How many years? 
 
Clopidogrel Use 
 If yes: What is the dose? 
  For how long? 
 
Aspirin Use 
 If yes: What is the dose? 
  For how long? 
 
ABCD2 Score (if TIA): ___________ 
 
NIHSS Score (if ischemic stroke): ___________ 
 




Baseline Laboratory Values: 
 




Alpha-tocopherol   
Total Cholesterol (mg/dL)  
LDL (mg/dL)  
HDL (mg/dL)  
Triglycerides (mg/dL)  
Chol/HDL Ratio (calculated)  
Non-HDL Cholesterol (mg/dL, calculated)  
WBC (K/uL)  
RBC (M/uL)  
Hgb (gm/dL)  
Hct (%vol)  
MCV (fl)  
Platelets (k/uL)  
MCH (pg)  
MCHC (g/dL)  
RDW (%)  
MPV (fl)  
Neutrophils (%)  
Lymphocytes (%)  
Eosinophils (%)  
Basophils (%)  
Neutrophils (K/uL)  
Lymphocytes (K/uL)  
Monocytes (K/uL)  
Basophils (K/uL)  
Eosinophils (K/uL)  
Serum Creatinine (mg/dL)  
BUN (mg/dL)  
Estimated GFR (mg/dL)  
BUN/Cr Ratio  
Glucose (mg/dL)  
Sodium (mmol/L)  
Potassium (mmol/L)  
Chloride (mmol/L)  
Carbon Dioxide (mmol/L)  
Calcium (mg/dL)  
Alkaline Phosphatase (U/L)  
Aspartate Aminotransferase (U/L)  
Alanine Aminotransferase (U/L)  
Bilirubin, Total (mg/dL)  
Protein, Total (g/dL)  
Albumin (g/dL)  
Globulin (g/dL)  
A/G Ratio  
Anion Gap  
  
 70 
Appendix C: ABCD2 Score1 
 
FOR TIA PATIENTS (SCORE MUST BE ≥ 4 TO QUALIFY) 
 
ABCD2 Score:  ____/7 
 
 










BP ≥140/90 (initial BP. Either 





































10-59 minutes (1 
point) 
 
≥60 minutes (2 
points) 
 
History of Diabetes 
 
 
No (0 points) 
 





Appendix D: Modified Rankin Scale (mRS)2 
 
FOR ALL PATIENTS 
 
Modified Rankin Scale (mRS) Score: 
 
Level Description 
0 No symptoms 
1 No significant disability; able to perform usual activities 
2 Slight disability: able to carry out own affairs but unable to perform previous activities without assistance 
3 Moderate disability: require some assistance but is able to walk without help 
4 Moderately-Severe disability; unable to walk or attend to bodily needs without assistance 
5 Severe disability; bedridden, incontinent, requires nursing care 













Appendix E: National Institute of Health Stroke Scale (NIHSS)3 
Minor ischemic stroke patients at time of randomization (score must be ≤ 3 to qualify)  
For all patients on day 90       NIHSS Score: ___/ 42 








Arouses to minor 
stimulation 
Requires repeated 
stimulation to arouse 
OR 






Ask Month & 
Age 
 
Both questions right 
1 question right OR 
Dysarthric/intubated/traum
a/ language barrier 







Perform both tasks 
 
Performs 1 task 
 









Partial gaze palsy: can be 
overcome OR 
Partial gaze palsy corrects 
with oculocephalic reflex 
 
Forced gaze palsy: 
cannot be overcome 
  
Visual Fields No visual loss Partial hemianopia Complete 
hemianopia 
Bilaterally blind OR 












Minor paralysis (flat 





















Drift, but doesn’t hit bed 
Drift, hits bed OR 
Some effort against 
gravity  











Drift, but doesn’t hit bed 
Drift, hits bed OR 
Some effort against 
gravity  











Drift, but doesn’t hit bed 
Drift, hits bed OR 
Some effort against 
gravity  











Drift, but doesn’t hit bed 
Drift, hits bed OR 
Some effort against 
gravity 
















Ataxia in 1 limb 
 
 












Mild-moderate loss: less 
sharp/duller OR 
Mild-moderate loss: can 
sense being touched 
Complete loss: can’t 
sense being touched 
at all OR 








































or out of proportion 










ial/personal inattention OR 
Extinction to bilateral 
simultaneous stimulation  
Profound hemi-
inattention (ex: does 
not recognize own 
hand) OR 




Appendix F: Patient Follow-Up 
 
Participant Identifying Number: ___________ 
Stroke Center Site: ___________ 
Name of Researcher: ___________ 
Today’s Date: ___________ 
 
Known Recurrent Stroke? ___________ 
 If yes, how many days after your index stroke? ___________ 
Known Myocardial Infarction? 





Morisky Scale Score: ___________ 
 
Disability 
Modified Rankin Scale Score: ___________ 
NIHSS Score (only if index event was minor ischemic stroke): ___________ 
 
Labs and Imaging (for day 90 only) 
Serum alpha-tocopherol level: ___________ 





MRI Findings (evidence of new infarction): ________________________________ 
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Questionnaire for Verifying Stroke-Free Status (QVSFS)4 
 
1. Were you ever told by a physician that you had a stroke? (since last visit) 
___ Yes  ___ No  ___ Unknown 
 
2. Were you ever told by a physician that you had a TIA, ministroke, or transient 
ischemic attack? (since last visit) 
___ Yes  ___ No  ___ Unknown 
 
3. Have you had sudden painless weakness on one side of your body?  
___ Yes  ___ No  ___ Unknown 
 
4. Have you had sudden numbness or a dead feeling on one side of your body? (since 
last visit) 
___ Yes  ___ No  ___ Unknown 
 
5. Have you had sudden painless loss of vision in one or both eyes? (since last visit) 
___ Yes  ___ No  ___ Unknown 
 
6. Have you suddenly lost one half of your vision? (since last visit) 
___ Yes  ___ No  ___ Unknown 
 
7. Have you suddenly lost the ability to understand what people are saying? (since last 
visit) 
 ___ Yes  ___ No  ___ Unknown 
 
8. Have you ever suddenly lost the ability to express yourself verbally or in writing? 
(since last visit) 
___ Yes  ___ No  ___ Unknown 
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Appendix G: Sample Size Calculation 
 
 
Using the Power and Precision 4, we determined that the trial will require at least 2,002 
participants, with 1,001 participants per arm, in order to provide 80% power to detect a rate 
difference of 3.2% in the vitamin E alpha-tocopherol group, with a two-sided type I error 
of 0.05 and an 6% withdrawal rate, assuming an 8.2% event rate in the group of aspirin 
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